Research programme: LHRH peptidomimetic antagonists - COSCIENS Biopharma
Alternative Names: AEZS-115; LHRH peptidomimetics - COSCIENS Biopharma/Solvay; ZEN-019Latest Information Update: 08 Aug 2024
At a glance
- Originator AEterna Zentaris Inc; Solvay Pharmaceuticals
- Developer AEterna Zentaris Inc; COSCIENS Biopharma
- Class
- Mechanism of Action Gonadotropin releasing hormone inhibitors; LHRH receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Cancer; Endometriosis
- Discontinued Endocrine disorders; Genitourinary disorders; Pregnancy
Most Recent Events
- 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in Europe (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Europe (PO)